Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein

10 Jan 2012

Abstract excerpt

BACKGROUND AND PURPOSE: Besides targeting the well-known oncogenic c-Met, crizotinib is the first oral tyrosine kinase inhibitor inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non-small cell lung cancer. Here, we assessed the possible reversal of multidrug resistance (MDR) by crizotinib in vitro and in vivo. EXPERIMENTAL APPROACH: 1-(4,5-Dimethylthiazol-2-yl)-3,5-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22233293
DOI: 10.1111/j.1476-5381.2012.01849.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoproteinPMID 22233293Read ↗

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug ResistanceSemantic proximity Read ↗

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivoSemantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.Semantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistance<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.Semantic proximity Read ↗

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter ProteinsSemantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studiesSemantic proximity Read ↗

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cellsSemantic proximity Read ↗

DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.